Alexion Pharmaceuticals, Inc. ALXN

Alexion Pharmaceuticals, Inc. Revenue 2011-2026 | ALXN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Alexion Pharmaceuticals, Inc.

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
6.07 B	4.99 B	4.13 B	3.55 B	3.08 B	2.6 B	2.23 B	1.55 B	1.13 B	783 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
6.07 B	783 M	3.01 B

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	21 M	$ 2.19	-9.77 %	$ 226 M	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Cabaletta Bio CABA	0.006	$ 3.34	0.45 %	$ 3.9 M	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Codexis CDXS	59.3 M	$ 1.02	1.49 %	$ 74.9 M	USA
AbCellera Biologics ABCL	75.1 M	$ 3.74	3.6 %	$ 1.12 B	Canada
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Cerus Corporation CERS	201 M	$ 2.6	1.37 %	$ 480 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Cellectis S.A. CLLS	41.5 M	$ 3.87	-0.39 %	$ 116 M	France
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Collegium Pharmaceutical COLL	205 M	$ 41.75	0.19 %	$ 1.32 B	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Corcept Therapeutics Incorporated CORT	761 M	$ 36.14	1.23 %	$ 3.75 B	USA
Amarin Corporation plc AMRN	307 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Catalyst Pharmaceuticals CPRX	589 M	$ 23.77	2.99 %	$ 2.91 B	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Corbus Pharmaceuticals Holdings CRBP	882 K	$ 8.41	-1.87 %	$ 36.4 M	USA
Cardiff Oncology CRDF	593 K	$ 1.94	0.01 %	$ 130 M	USA
Curis CRIS	10.9 M	$ 1.1	-3.51 %	$ 6.94 M	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
CorMedix CRMD	65.4 K	$ 7.16	0.42 %	$ 364 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Champions Oncology CSBR	56.9 M	$ 6.14	3.89 %	$ 83.9 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Citius Pharmaceuticals CTXR	90 K	$ 0.72	-2.34 %	$ 4.84 M	USA
Aridis Pharmaceuticals ARDS	3.09 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	20 K	$ 4.21	-2.32 %	$ 299 M	USA
CEL-SCI Corporation CVM	255 K	$ 3.88	-8.92 %	$ 247 M	USA